Drug that starves tumors shows promise against advanced kidney cancer
NCT ID NCT00403169
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase II trial tests the drug lenalidomide (CC-5013) in people with advanced or inoperable kidney cancer. Lenalidomide works by cutting off blood flow to tumors, which may stop or slow their growth. The study aims to see how many patients respond to treatment and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide (also called CC-5013)
What this could lead to
If it works, lenalidomide could offer a new treatment option for people with advanced kidney cancer that cannot be removed by surgery.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. Lenalidomide can cause serious side effects, and the cancer may still grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AMPLIFI: Web-Based Lifestyle Program for Cancer NCT04000880
- UDCA for Kidney Protection in Partial Nephrectom NCT07672860
- Nivolumab in Advanced Kidney Cancer: Real-World NCT03455452
- I CARE Trial: Managing Immunotherapy Side Effect NCT07646847
- KVA12123 Cancer Trial for Advanced Solid Tumors NCT05708950
- Marathon of Hope Cancer Study (NCT05403177)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065, United States